Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro

Nicoletta Gagliano, Letizia Pettinari, Massimo Aureli, Carla Martinelli, Elena Colombo, Francesco Costa, Roberta Carminati, Tatiana Volpari, Graziano Colombo, Aldo Milzani, Isabella Dalle-Donne, Magda Gioia

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluorescence as well as actin and tubulin; matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was analyzed by SDS-zymography, intracellular and secreted SPARC levels by western blot, and cell cycle by flow cytometry. Ukrain did not induce E-cadherin/β-catenin immunoreactivity at the cell-cell boundary, although it determined the actin cortical expression in Caki-2 and ACHN, and did not affect vimentin organization; however, in some Caki-1 and ACHN cells the perinuclear concentration of vimentin was consistent with its downregulation. Matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was significantly downregulated 48 h after 20 μmol/l Ukrain administration. At this time point, Ukrain significantly decreased migration and invasion, and downregulated SPARC levels in cell supernatants at all doses in Caki-2, and at 20 μmol/l in Caki-1 and ACHN cells. Concomitantly, SPARC was upregulated in all ccRCC cells, suggesting that Ukrain could also affect cell proliferation by cell cycle inhibition, as supported by the cell cycle analysis, as SPARC also acts as a cell cycle inhibitor. Our results suggest that Ukrain may switch the epithelial-to-mesenchymal transition-related phenotype of ccRCC cells, and targets the two major aspects involved in RCC progression, such as tumor invasion/microenvironment remodeling and cell proliferation.

Original languageEnglish
Pages (from-to)749-762
Number of pages14
JournalAnti-Cancer Drugs
Volume22
Issue number8
DOIs
Publication statusPublished - Sep 2011

Fingerprint

ukrain
Renal Cell Carcinoma
Phenotype
Cell Cycle
Vimentin
Catenins
Epithelial-Mesenchymal Transition
Down-Regulation
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Cadherins
Actins
Cell Proliferation
Naphazoline
Tumor Microenvironment
In Vitro Techniques
Tubulin
Fluorescent Antibody Technique
Flow Cytometry

Keywords

  • cytoskeleton
  • epithelial-to-mesenchymal transition
  • matrix metalloproteinases
  • renal cell carcinoma
  • secreted protein acidic and rich in cysteine
  • tumor invasion

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Gagliano, N., Pettinari, L., Aureli, M., Martinelli, C., Colombo, E., Costa, F., ... Gioia, M. (2011). Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro. Anti-Cancer Drugs, 22(8), 749-762. https://doi.org/10.1097/CAD.0b013e328346c7f7

Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro. / Gagliano, Nicoletta; Pettinari, Letizia; Aureli, Massimo; Martinelli, Carla; Colombo, Elena; Costa, Francesco; Carminati, Roberta; Volpari, Tatiana; Colombo, Graziano; Milzani, Aldo; Dalle-Donne, Isabella; Gioia, Magda.

In: Anti-Cancer Drugs, Vol. 22, No. 8, 09.2011, p. 749-762.

Research output: Contribution to journalArticle

Gagliano, N, Pettinari, L, Aureli, M, Martinelli, C, Colombo, E, Costa, F, Carminati, R, Volpari, T, Colombo, G, Milzani, A, Dalle-Donne, I & Gioia, M 2011, 'Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro', Anti-Cancer Drugs, vol. 22, no. 8, pp. 749-762. https://doi.org/10.1097/CAD.0b013e328346c7f7
Gagliano, Nicoletta ; Pettinari, Letizia ; Aureli, Massimo ; Martinelli, Carla ; Colombo, Elena ; Costa, Francesco ; Carminati, Roberta ; Volpari, Tatiana ; Colombo, Graziano ; Milzani, Aldo ; Dalle-Donne, Isabella ; Gioia, Magda. / Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro. In: Anti-Cancer Drugs. 2011 ; Vol. 22, No. 8. pp. 749-762.
@article{014e79ea68684134a759a7000ffb6657,
title = "Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro",
abstract = "We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluorescence as well as actin and tubulin; matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was analyzed by SDS-zymography, intracellular and secreted SPARC levels by western blot, and cell cycle by flow cytometry. Ukrain did not induce E-cadherin/β-catenin immunoreactivity at the cell-cell boundary, although it determined the actin cortical expression in Caki-2 and ACHN, and did not affect vimentin organization; however, in some Caki-1 and ACHN cells the perinuclear concentration of vimentin was consistent with its downregulation. Matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was significantly downregulated 48 h after 20 μmol/l Ukrain administration. At this time point, Ukrain significantly decreased migration and invasion, and downregulated SPARC levels in cell supernatants at all doses in Caki-2, and at 20 μmol/l in Caki-1 and ACHN cells. Concomitantly, SPARC was upregulated in all ccRCC cells, suggesting that Ukrain could also affect cell proliferation by cell cycle inhibition, as supported by the cell cycle analysis, as SPARC also acts as a cell cycle inhibitor. Our results suggest that Ukrain may switch the epithelial-to-mesenchymal transition-related phenotype of ccRCC cells, and targets the two major aspects involved in RCC progression, such as tumor invasion/microenvironment remodeling and cell proliferation.",
keywords = "cytoskeleton, epithelial-to-mesenchymal transition, matrix metalloproteinases, renal cell carcinoma, secreted protein acidic and rich in cysteine, tumor invasion",
author = "Nicoletta Gagliano and Letizia Pettinari and Massimo Aureli and Carla Martinelli and Elena Colombo and Francesco Costa and Roberta Carminati and Tatiana Volpari and Graziano Colombo and Aldo Milzani and Isabella Dalle-Donne and Magda Gioia",
year = "2011",
month = "9",
doi = "10.1097/CAD.0b013e328346c7f7",
language = "English",
volume = "22",
pages = "749--762",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro

AU - Gagliano, Nicoletta

AU - Pettinari, Letizia

AU - Aureli, Massimo

AU - Martinelli, Carla

AU - Colombo, Elena

AU - Costa, Francesco

AU - Carminati, Roberta

AU - Volpari, Tatiana

AU - Colombo, Graziano

AU - Milzani, Aldo

AU - Dalle-Donne, Isabella

AU - Gioia, Magda

PY - 2011/9

Y1 - 2011/9

N2 - We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluorescence as well as actin and tubulin; matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was analyzed by SDS-zymography, intracellular and secreted SPARC levels by western blot, and cell cycle by flow cytometry. Ukrain did not induce E-cadherin/β-catenin immunoreactivity at the cell-cell boundary, although it determined the actin cortical expression in Caki-2 and ACHN, and did not affect vimentin organization; however, in some Caki-1 and ACHN cells the perinuclear concentration of vimentin was consistent with its downregulation. Matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was significantly downregulated 48 h after 20 μmol/l Ukrain administration. At this time point, Ukrain significantly decreased migration and invasion, and downregulated SPARC levels in cell supernatants at all doses in Caki-2, and at 20 μmol/l in Caki-1 and ACHN cells. Concomitantly, SPARC was upregulated in all ccRCC cells, suggesting that Ukrain could also affect cell proliferation by cell cycle inhibition, as supported by the cell cycle analysis, as SPARC also acts as a cell cycle inhibitor. Our results suggest that Ukrain may switch the epithelial-to-mesenchymal transition-related phenotype of ccRCC cells, and targets the two major aspects involved in RCC progression, such as tumor invasion/microenvironment remodeling and cell proliferation.

AB - We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluorescence as well as actin and tubulin; matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was analyzed by SDS-zymography, intracellular and secreted SPARC levels by western blot, and cell cycle by flow cytometry. Ukrain did not induce E-cadherin/β-catenin immunoreactivity at the cell-cell boundary, although it determined the actin cortical expression in Caki-2 and ACHN, and did not affect vimentin organization; however, in some Caki-1 and ACHN cells the perinuclear concentration of vimentin was consistent with its downregulation. Matrix metalloproteinase-2 and matrix metalloproteinase-9 activity was significantly downregulated 48 h after 20 μmol/l Ukrain administration. At this time point, Ukrain significantly decreased migration and invasion, and downregulated SPARC levels in cell supernatants at all doses in Caki-2, and at 20 μmol/l in Caki-1 and ACHN cells. Concomitantly, SPARC was upregulated in all ccRCC cells, suggesting that Ukrain could also affect cell proliferation by cell cycle inhibition, as supported by the cell cycle analysis, as SPARC also acts as a cell cycle inhibitor. Our results suggest that Ukrain may switch the epithelial-to-mesenchymal transition-related phenotype of ccRCC cells, and targets the two major aspects involved in RCC progression, such as tumor invasion/microenvironment remodeling and cell proliferation.

KW - cytoskeleton

KW - epithelial-to-mesenchymal transition

KW - matrix metalloproteinases

KW - renal cell carcinoma

KW - secreted protein acidic and rich in cysteine

KW - tumor invasion

UR - http://www.scopus.com/inward/record.url?scp=80051521857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051521857&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e328346c7f7

DO - 10.1097/CAD.0b013e328346c7f7

M3 - Article

C2 - 21799470

AN - SCOPUS:80051521857

VL - 22

SP - 749

EP - 762

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -